OMNIAB, INC. Current Assets
OMNIAB, INC. (OABI) had Current Assets of $66.01 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-06
- 2026-06-30: Assets, Current $66.01M.
- 2026-03-31: Assets, Current $65.13M.
- 2025-12-31: Assets, Current $65.34M.
- 2025-09-30: Assets, Current $66.35M.
| Period end | Assets, Current | Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $66.01M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $65.13M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $65.34M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $66.35M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $47.62M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $53.58M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $68.14M 10-K · filed 2026-03-04 | |
| 2024-09-30 | $66.61M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $67.30M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $76.72M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $94.90M 10-K · filed 2025-03-18 | |
| 2023-09-30 | $106.85M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $115.94M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $121.08M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $124.95M 10-K · filed 2024-03-25 | |
| 2022-11-01 | $100.30M 10-K · filed 2024-03-25 | |
| 2022-09-30 | $423.87K 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $692.01K 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $1.10M 10-Q · filed 2022-05-20 | |
| 2021-12-31 | $22.54M 10-K · filed 2023-03-30 | $934.51K 10-K · filed 2022-03-28 |
| 2021-09-30 | $1.24M 10-Q/A · filed 2022-01-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |